Clinical trials: Motor Fluctuations
Parkinson's Disease, Off Episodes of Parkinson Disease
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Trial name
- NCT03187301
- Testing
- APL-130277, Moxifloxacin
- Where
- 15 sites in United States, Italy
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Idiopathic Parkinson's Disease
Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease
Medical treatment of idiopathic Parkinson disease motor symptoms requires dopaminergic drugs, with long term disabling side effects. (fluctuations, dyskinesia, ON/OFF phenomena).
- Trial name
- NICOPARK2 (NCT00873392)
- Testing
- Transdermal nicotine, Usual drug treatment of Parkinson's disease
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
BDNF
Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognition: Effects of Vigorous Exercise
Cognitive functions are fundamental to everyday life, underpinning the mental processes required to perform any activity. Recent studies have shown that improved cognitive performance is associated with elevated levels of…
- Trial name
- NCT07385118
- Testing
- Exercise
- Where
- Italy
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Padova
Parkinson's Disease
Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Parkinson's Disease (PD) is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons.
- Trial name
- NCT00865579
- Testing
- Safinamide
- Where
- Romania
- Volunteers
- 964 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson, Parkinson Disease
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
Patients with Parkinson's disease (PD) are commonly treated with a combination of levodopa and a decarboxylase inhibitor (DCI). However, many PD patients experience motor fluctuations (OFF episodes), even with their regular…
- Conditions
- Parkinson, Parkinson Disease, Parkinson's Disease and Parkinsonism
- Trial name
- NCT06037590
- Testing
- Levodopa Cyclops®, INBRIJA®
- Where
- Bulgaria
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- PureIMS B.V.
Parkinson's Disease
Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease
The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication.
- Trial name
- NCT00584025
- Testing
- levetiracetam
- Where
- United States
- Sponsor
- University of South Florida
Parkinson's Disease
Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale in Parkinson's Disease
This study focuses on neuropsychiatric fluctuations (NPF) in Parkinson's disease. Due to the lack of specific assessment tools, we developed the Neuropsychological Fluctuations Scale (NFS), a 20-item questionnaire.
- Trial name
- EFN-RETEST (NCT06701955)
- Testing
- Questionnaire and Physical Exam
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Grenoble
Parkinson Disease
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated…
- Trial name
- NCT03292016
- Testing
- APL-130277, APO-go, Apokyn
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00357994
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 15 sites in United States, Germany
- Volunteers
- 36 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetes Mellitus, Type 1, Exercise
Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring
The purpose of this project is to investigate whether the glucose response in type 1 diabetes patients measured using Continuous Glucose Monitoring measurement is reproducible in repeated standardized test sessions that include…
- Conditions
- Diabetes Mellitus, Type 1, Exercise, Continuous Glucose Monitoring
- Trial name
- NCT02942069
- Testing
- Blood glucose measured using CGM during standardized physical activity
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Nordsjaellands Hospital
Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank…
- Trial name
- NCT05766813
- Testing
- Lenrispodun
- Where
- 35 sites in United States
- Volunteers
- 79 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Parkinson Disease
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor…
- Trial name
- ATLANTIS (NCT06055985)
- Testing
- UCB0022
- Where
- 61 sites in United States
- Volunteers
- 207 people
- Sponsor
- UCB Biopharma SRL
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
- Trial name
- NCT02542696
- Testing
- APL-130277
- Where
- 70 sites in United States, Austria and 6 more
- Volunteers
- 496 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson's Disease With Motor Fluctuations
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT03185481
- Testing
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Parkinson's Disease
Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
In this first study of inhaled apomorphine in Parkinson's disease patients, the primary objective is to find the minimum efficacious dose of apomorphine that is useful in rescuing patients during 'off' periods.
- Trial name
- NCT01683292
- Testing
- Inhaled VR040
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- South Glasgow University Hospitals NHS Trust
Parkinson Disease
OpiCapone Effect on Motor Fluctuations and pAiN
The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with…
- Trial name
- OCEAN (NCT04986982)
- Testing
- Opicapone 50 mg
- Where
- United Kingdom
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor…
- Trial name
- NCT00143026
- Testing
- carbidopa, levodopa, entacapone
- Where
- 18 sites in Australia, Philippines and 2 more
- Volunteers
- 184 people
- Sponsor
- Novartis
PARKINSON DISEASE (Disorder)
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
This study is a Phase III multicentric randomized controlled trial with parallel group design and waiting list in patients that have an indication to undergo intestinal L-Dopa + entacapone (Lecigon®) under the existing indication…
- Trial name
- INITIATE-LECIG (NCT07151378)
- Testing
- LECIG (levodopa, carbidopa, entacapone intestinal gel), Best oral medication
- Where
- 7 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University Hospital Tuebingen
Dyskinesias, Parkinson Disease
Levetiracetam Treatment of L-dopa Induced Dyskinesias
This study will evaluate the effects of levetiracetam (Keppra (Trademark) on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa.
- Trial name
- NCT00076674
- Testing
- Intravenous Levodopa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)